Puedes cambiar tus opciones en cualquier momento visitando Tus controles de privacidad. Since our founding in 2007, Akebia (Nasdaq: AKBA) has been focused on achieving better outcomes for people with kidney disease. Within the Finance Sector, it would fall into the M Industry of Banks & Thrifts. On the bottom line, Akebia Therapeutics reported a net loss of $87 million -- $0.60 per share -- compared to the net loss and net loss per share of $94.5 million and $0.79 respectively that it recorded during the fourth quarter of the previous fiscal year. Of note is the ratio of Akebia Therapeutics Inc's sales and general administrative expense to its total operating expenses; just 22.54% of US stocks have a lower such ratio. Información sobre tu dispositivo y conexión a Internet, incluida tu dirección IP, Actividad de navegación y búsqueda al utilizar sitios web y aplicaciones de Verizon Media. Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -82.61% and -21.20%, respectively, for the quarter ended September 2020. Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.23. AKBA Stock Summary. ... Yahoo Finance UK 'The virus has taken off': Alarming study says 45,000 people get COVID every day in England. Make 2021 your best (financial) year yet with Yahoo Finance's free daily newsletter. The stock has moved higher by 55% in the past month, while it is also above its 20 Day SMA too. In terms of volatility of its share price, AKBA is more volatile than 95.62% of stocks we're observing. Investors in Akebia Therapeutics, Inc. AKBA need to pay close attention to the stock based on moves in the options market lately. Find the latest Akebia Therapeutics, Inc. (AKBA) stock quote, history, news and other vital information to help you with your stock trading and investing. Anheuser-Busch Inbev Stock is a Must Own Re-Opening Play. Para permitir a Verizon Media y a nuestros socios procesar tus datos personales, selecciona 'Acepto', o selecciona 'Gestionar ajustes' para obtener más información y para gestionar tus opciones. Yahoo News. As of late, it has definitely been a great time to be an investor in Akebia Therapeutics, Inc. (AKBA). DOW 32,297.02. As with many other companies Akebia Therapeutics, Inc. (NASDAQ:AKBA) makes use of debt. Investors in Akebia Therapeutics, Inc. AKBA need to pay close attention to the stock based on moves in the options market lately. Google Finance provides real-time market quotes, international exchanges, up-to-date financial news, and analytics to help you make more informed trading and investment decisions. Share your opinion and gain insight from other stock traders and investors. The latest economy, property, and money news, tips and advice: straight to your inbox. Find the latest Akebia Therapeutics, Inc. (AKBA) stock discussion in Yahoo Finance's forum. Find the latest Akebia Therapeutics, Inc. (AKBA) stock quote, history, news and other vital information to help you with your stock trading and investing. On average, analysts expected the company's net loss per share to be $0.40. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $2.39 to $3.11 in the past one-month time frame. finance.yahoo.com - November 5 at 11:41 PM: Akebia Therapeutics (AKBA) Reports Q3 Loss, Lags Revenue Estimates finance.yahoo.com - November 5 at 1:40 PM: Akebia Reports Third Quarter 2020 Financial Results and Recent Business Updates finance.yahoo.com - November 5 at 8:40 AM That is because the Jan 15, 2021 $5.00 Call had some of the highest implied volatility of all equity options today. Akebia Therapeutics, Inc.'s (NASDAQ:AKBA): Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal … This quarterly report represents an earnings surprise of … Share your opinion and gain insight from other stock traders and investors. At Yahoo Finance, you get free stock quotes, the latest news, portfolio management resources, international market data, social interaction and mortgage rates to help you manage your financial life. AKBA closed up 8.11 percent on Tuesday, March 9, 2021, on 64 percent of normal volume. Yahoo News UK. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously... Akebia Therapeutics' total revenue of $56.7 million for its fourth quarter, ending Dec. 31, beat the consensus analyst estimate, which was $51.16 million. The Zacks rating relies solely on a company's changing earnings picture. Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 6 newly-hired employees options to purchase an aggregate of 27,000 shares of Akebia's common stock on October 30, 2020, as inducements material to each … Yahoo forma parte de Verizon Media. The stock has moved higher by 55% in the past month, while it is also above its 20 Day SMA too. Find the latest Akebia Therapeutics, Inc. (AKBA) stock quote, history, news and other vital information to help you with your stock trading and investing. NZ business & finance news, stock quotes, currency information and blogs Find the latest Akebia Therapeutics, Inc. (AKBA) stock discussions in Yahoo Finance's forum.